About
Overview
Company Leadership
Science
Technology Platform
Scientific Publications
Pipeline
Overview
CF101
CF102
CF602
Investor Information
Overview
News / Events
Company Information
Financial Information
Stock Information
SEC Filings
Corporate Governance
Shareholders Meetings
Contact Us
Directions
Investor Information
Overview
News / Events
Press Releases
In The News
Research
Events Calendar
Presentations
Email Alerts
Company Information
Profile
Management
IR Contacts
FAQ
Financial Information
Quarterly & Annual Reports
Stock Information
Quote
Charts
Historical Data
SEC Filings
All SEC Filings
Section 16 Filings
Corporate Governance
Board of Directors
Governance Docs
Shareholders Meetings
Email Alerts
IR Contacts
RSS News Feed
Press Releases
All News
By Year:
2019
2018
2017
2016
2015
2014
2013
2012
Dec 30, 2014 7:00 AM EST
Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101
Dec 22, 2014 7:00 AM EST
Can-Fite Doses First Patient in Global Phase II Liver Cancer Trial for CF102
Dec 15, 2014 7:02 AM EST
Second Part of the Glaucoma Phase II study has been Approved in a European Country
Dec 9, 2014 7:00 AM EST
Can-Fite to Initiate the Development Program of its Next Generation Drug CF602
Dec 2, 2014 5:49 PM EST
Can-Fite Announces $8 Million At-The-Market Registered Direct Offering
Dec 1, 2014 7:00 AM EST
US Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101
Dec 1, 2014 7:00 AM EST
Can-Fite Reports Financial Results for Nine Months Ended September 30, 2014
Nov 18, 2014 7:00 AM EST
Can-Fite Near-Term Milestones Timetable for 2014/2015
Nov 17, 2014 5:48 PM EST
Can-Fite Announces Special General Meeting of Shareholders to Elect External Director
Nov 13, 2014 7:00 AM EST
Can-Fite CEO Dr. Pnina Fishman to Present Recently Released Positive Data from its Rheumatoid Arthritis Phase IIb Study at the 2014 American College of Rheumatology Annual Meeting
1
2
3
4
5
Next >>
Show All
